BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8320924)

  • 21. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
    Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in fibrinolytic activity during the course of a single hemodialysis session.
    Kurz H; Lerner RG; Weseley S; Nelson JC
    Clin Nephrol; 1985 Jul; 24(1):1-4. PubMed ID: 4040447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
    Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
    Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human gender differences in fibrinolytic responses to exercise training and their determinants.
    Kulaputana O; Macko RF; Ghiu I; Phares DA; Goldberg AP; Hagberg JM
    Exp Physiol; 2005 Nov; 90(6):881-7. PubMed ID: 16118237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of blood passage through the pulmonary circulation on fibrinolytic parameters.
    Kloboves-Prevodnik V; Sabovic M; Keber D
    Heart Vessels; 2004 Jan; 19(1):33-7. PubMed ID: 14685753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M; Mavri A
    Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
    Mansfield MW; Catto AJ; Carter AM; Grant PJ
    Diabet Med; 1998 Nov; 15(11):953-7. PubMed ID: 9827850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
    Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
    J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
    Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
    J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
    Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
    J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
    Speidl WS; Nikfardjam M; Niessner A; Zeiner A; Jordanova N; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
    Thromb Res; 2007; 119(3):331-6. PubMed ID: 16616324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction].
    Yamada S; Yamada R; Ishii A; Ashikawa K; Nakamura M; Sasamata M; Watanabe S
    Rinsho Byori; 1990 Jul; 38(7):819-24. PubMed ID: 2119465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
    Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.
    Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E
    Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
    Orbe J; Chordá C; Montes R; Páramo JA
    Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What are the factors contributing to the changes in tissue-type plasminogen activator during haemodialysis?
    Opatrný K; Opatrný K; Vít L; Racek J; Válek A
    Nephrol Dial Transplant; 1991; 6 Suppl 3():26-30. PubMed ID: 1775262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.